High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova

European Respiratory Journal

Volumn 43, Issue 4, 2014, Pages 1132-1141

  Jenkins, Helen E ^a,b   Crudu, Valeriu ^c   Soltan, Viorel ^c   Ciobanu, Ana ^d   Domente, Liliana ^d   Cohen, Ted ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Center for Health Policies and Studies   (Moldova)

^e Microbiology and Morphology Laboratory   (Moldova)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGE DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MIXED INFECTION; MOLDOVA; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPUTUM EXAMINATION; TUBERCULOSIS; COMPLICATION; MIDDLE AGED; TIME; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; COINFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOLDOVA; PREVALENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84897430191     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00203613     Document Type: Conference Paper

References (41)

1. World Health Organization. Global Tuberculosis Report 2013. Geneva, WHO Press, 2013.
2. Zignol M, van Gemert W, Falzon D, et al Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111D-119D.
3. Skrahina A, Hurevich H, Zalutskaya A., et al Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
4. World Health Organization. Towards Universal Access to Diagnosis and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis by 2015: WHO Progress Report 2011. Geneva, WHO Press, 2011.
5. World Health Organization. Roadmap to Prevent and Combat Drug-Resistant Tuberculosis. Copenhagen, WHO Regional Office for Europe, 2011.
6. National Bureau of Statistics of the Republic of Moldova. Population Census Results Chisinau 2004. www.statistica.md/pageview.php?l=en&idc=295 Date last accessed: February 6, 2014. Date last updated: February 6, 2014.
7. Jenkins HE, Plesca V, Ciobanu A., et al Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J 2013; 42: 1291-1301.
8. Soltan V, Henry AK, Crudu V, et al Increasing tuberculosis case detection: lessons from the Republic of Moldova. Bull World Health Organ 2008; 86: 71-76.
9. Jenkins HE, Ciobanu A, Plesca V., et al Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. Int J Tuberc Lung Dis 2013; 17: 373-380.
10. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
11. Crudu V.R.-G.S., Niemann S, Moraru N, et al. Nosocomial transmission of multidrug-resistant M.tuberculosis strains in a high incidence setting. Int J Tuberc Lung Dis 2010; Suppl. 1, S353.
12. Nodieva A, Jansone I, Broka L., et al Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2010; 14: 427-433.
13. van Rie A., Victor TC, Richardson M, et al Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005; 172: 636-642.
14. Cohen T, van Helden PD, Wilson D, et al Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev 2012; 25: 708-719.
15. Hingley-Wilson S.M., Casey R, Connell D., et al Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection. Emerg Infect Dis 2013; 19: 1138-1141.
16. Falzon D, Gandhi N, Migliori G.B., et al Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
17. World Health Organization. Multidrug and Extensively Drug-Resistant (M/XDR-TB). 2010 Global Report on Surveillance and Response. Geneva, WHO Press, 2010.
18. Crudu V, Soltan V, Burinschi V., et al Anti-tuberculosis drug resistance surveillance, Republic of Moldova, 2006. Chisinau, Elena-V.I., 2009.
19. World Health Organization. Treatment of Tuberculosis Guidelines, 4th Edn. Geneva, WHO Press, 2010.
20. Ministry of Health and Social Protection, Moldovan Government. Cu privire la implementarea progamului national de control si profilaxie a tuberculozei in Republica Moldova, pentru anii 2006-2010 [Implementation of the National Program for the Control and Prevention of Tuberculosis in Moldova, for 2006-2010.]. Order 180, Annex 11. Chisinau, Ministry of Health and Social Protection, 2006.
21. Falzon D, Jaramillo E, Schunemann H.J., et al WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
22. Cercone J. Technical Assistance to the Ministry of Health and the National TB Program in Investment Planning and Improvement of TB service Delivery System in The Republic of Moldova: Consultancy Report. Miami, Sanigest, 2013.
23. Turnbull BW. Empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Series B Stat Methodol 1976; 38: 290-295.
24. Collett D. Modelling Survival Data in Medical Research. 2nd Edn. Boca Raton, Chapman and Hall/CRC, 2003.
25. SAS Institute Inc. Chapter 48. In SAS/STAT 9.2 User's Guide. The LIFEREG Procedure. Cary, NC, SAS Institute Inc, 2009. pp. 2990-3095.
26. Gelmanova IY, Keshavjee S, Golubchikova V.T., et al Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711.
27. Migliori GB, Zellweger JP, Abubakar I, et al European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
28. Shin SS, Keshavjee S, Gelmanova I.Y., et al Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182: 426-432.
29. Porco TC, Oh P, Flood JM Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006. Clin Infect Dis 2013; 56: 761-769.
30. Ershova JV, Kurbatova EV, Moonan P.K., et al Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis 2012; 55: 1600-1607.
31. Lew W, Pai M, Oxlade O., et al Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-34.
32. Cox HS, Niemann S, Ismailov G., et al Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis 2007; 44: 1421-1427.
33. Seung KJ, Gelmanova IE, Peremitin G.G., et al The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004; 39: 1321-1328.
34. Migliori GB, Sotgiu G, Gandhi N.R., et al Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
35. Sotgiu G, D'Ambrosio L, Centis R, et al TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel? Eur Respir J 2011; 38: 1221-1223.
36. Cox HS, Kubica T, Doshetov D., et al The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res 2005; 6: 134.
37. Niemann S, Diel R, Khechinashvili G., et al Mycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia. J Clin Microbiol 2010; 48: 3544-3550.
38. Ford CB, Shah RR, Maeda M.K., et al Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013; 45: 784-790.
39. Köser C.U., Bryant JM, Becq J, et al Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013; 369: 290-292.
40. Sun G, Luo T, Yang C., et al Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 2012; 206: 1724-1733.
41. Weyer K, Mirzayev F, Migliori G.B., et al Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.